Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT  Shuichi.

Published by학표 여 Modified over 5 years ago

Similar presentations

Presentation on theme: "Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT  Shuichi."— Presentation transcript:

1 Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT  Shuichi Nishimura, MD, Atsuya Takeda, MD, PhD, Naoko Sanuki, MD, PhD, Sachiko Yoshida, MD, PhD, Naoyuki Shigematsu, MD, PhD  Journal of Thoracic Oncology  Volume 10, Issue 8, Pages e69-e71 (August 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Case 1: A, [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) before the initial stereotactic body radiotherapy (SBRT). The maximum standardized uptake value (SUVmax) was 3.3. B, Planning CT with dose distribution curves of the initial SBRT. A prescribed dose of 50 Gy was delivered in five fractions, with isodose lines from outer to inner representing 20, 30, 40, 50, and 60 Gy. C, 18F-FDG-PET/CT at 24 months after the initial SBRT (SUVmax: 6.7). D, Planning CT with dose distribution curves of salvage SBRT. A prescribed dose of 60 Gy was delivered in five fractions, with isodose lines from outer to inner representing 20, 40, 60, 80, and 90 Gy. E, 18F-FDG-PET/CT (SUVmax: 3.4) and (F) plain CT obtained 12 months after salvage SBRT. Journal of Thoracic Oncology  , e69-e71DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Case 2: A, [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) before the initial stereotactic body radiotherapy (SBRT). The maximum standardized uptake value (SUVmax) was 9.0. B, Planning CT with dose distribution curves of the initial SBRT. A prescribed dose of 50 Gy was delivered in five fractions, with isodose lines from outer to inner representing 20, 30, 40, 50, and 60 Gy. C, 18F-FDG-PET/CT at 10 months after the initial SBRT (SUVmax: 4.4). D, Planning CT with dose distribution curves of salvage SBRT. A prescribed dose of 60 Gy was delivered in five fractions, with isodose lines from outer to inner representing 20, 40, 60, 80, and 90 Gy. E, 18F-FDG-PET/CT (SUVmax: 2.1) and (F) plain CT obtained 36 months after salvage SBRT. Journal of Thoracic Oncology  , e69-e71DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT  Shuichi."

Similar presentations

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost?  Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost?  Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.
Jeffrey Bradley, MD  Journal of Thoracic Oncology 

Jeffrey Bradley, MD  Journal of Thoracic Oncology 
Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.
Gingival Metastasis as First Sign of Multiorgan Dissemination of Epithelioid Malignant Mesothelioma  Andrea Billè, Marco Platania, Giuseppe Pelosi, Barbara.

Gingival Metastasis as First Sign of Multiorgan Dissemination of Epithelioid Malignant Mesothelioma  Andrea Billè, Marco Platania, Giuseppe Pelosi, Barbara.
Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy  Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc.

Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy  Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc.
18F-Sodium Fluoride PET–CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma  Stefania Gori, MD, Alessandro Inno, MD, PhD, Gianluigi Lunardi,

18F-Sodium Fluoride PET–CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma  Stefania Gori, MD, Alessandro Inno, MD, PhD, Gianluigi Lunardi,
Salvage Stereotactic Ablative Irradiation for Isolated Postsurgical Local Recurrence of Lung Cancer  Atsuya Takeda, MD, PhD, Naoko Sanuki, MD, Takahisa.

Salvage Stereotactic Ablative Irradiation for Isolated Postsurgical Local Recurrence of Lung Cancer  Atsuya Takeda, MD, PhD, Naoko Sanuki, MD, Takahisa.
Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 
Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer  Masatsugu Hamaji,
Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments  Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments  Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Similar presentations

Ads by Google